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Abstract 
Background: Acute lymphoblastic leukemia (ALL) in adults tends to have a poor 
prognosis and even more challenging to treat during pregnancy due to the mother and 
the fetus’s safety issue. Despite commonly found in 2nd and 3rd trimester, ALL found 
during 2nd trimester needs more comprehensive management on maintaining the preg-
nancy while chemotherapy cannot be delayed. 
Case Presentation: A 36-year-old woman at 27 weeks of gestation visited the hospital 
with multiple cervical lymphadenopathy and major weight loss for the last six months. 
Bicytopenia with leukocytosis was found, along with an increase in LDH, Ferritin, and 
low albumin level. Bone marrow biopsy had confirmed the diagnosis of ALL-L2. Pos-
itive immunophenotyping results on HLA-DR, CD10, CD19, CD20, which support 
the lymphoid Line-B subtype. The patient was treated with Vincristine 2 mg/IV weekly 
and 100 mg of oral prednisone for six weeks and maintain the pregnancy. Successful 
delivery was carried out at 32 weeks of gestational age by lower segment cesarean 
section due to premature rupture of the membrane. A baby girl was born weighed 1700 
gram, APGAR Score 8/9/9, and has no disability on clinical or hematological features 
at the moment. 
Conclusion: ALL in pregnancy is very rare and extremely aggressive disease unless 
promptly treated. In this case report, it was a first pregnancy in advanced maternal age 
mother with high social value baby and can be treated successfully using single regi-
men of chemotherapy during pregnancy even though at the first time administered to 
hospital the mother come with critical clinical presentation. Leukemia in pregnancy is 
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INTRODUCTION 
 During pregnancy, 90% of leukemia cases are an 
acute process and chronic in the other ten, with two-
thirds of the cases, are myeloid.1 Leukemia in pregnancy 
is commonly diagnosed in the 2nd and 3rd trimesters, 
although the disease may pre-exist. This emphasizes the 
importance of early bone marrow examination for unex-
plained anemia in pregnancy. Early diagnosis is needed 
to monitor the patient’s and her baby's condition 
closely.2 
 ALL is rare in adults and rarer in pregnancy. Phila-
delphia chromosome (Ph)-positive ALL represents the 
major cytogenetic abnormality in adults (20-30%) and is 
associated with a poorer prognosis than Ph-negative 
ALL.3,4 Chemotherapy exposure in the first trimester 
may lead to congenital malformations or abortion. Sec-
ond and third-trimester chemotherapy exposure is associ-
ated with low birth weight, stunted fetal growth, sponta-
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 Recently, the prognosis of Ph-positive ALL has im-
proved markedly after BCR-Abl targeted tyrosine kinase 
inhibitors (TKI) were introduced. With upfront TKI, ap-
proximately 90 % of patients achieved complete remis-
sion (CR).6 However, the safety use of TKI for preg-
nancy is still under debate because of the low molecule 
that can transferred transplacental cause severe adverse 
effects and teratogenic effects have been reported, makes 
TKI in pregnancy should be avoided if possible.7 Before 
starting chemotherapy in pregnancy, the mother's poten-
tial benefits should be considered against the mother and 
fetus's potential risks. Besides, the chemotherapy proce-
dure is not easily accepted by pregnant women education 
on potential benefits and risks should be discussed to 
achieve the treatment goal. 
 
CASE REPORTS  
 A 36 years old female primigravida at 27 weeks of 
gestation presented to the emergency room with progres-
sive weakness in the last week. The complaint was ac-
companied by swelling on both upper eyelids, enlarged 
multiple neck-lymph nodes, heartburn, and fatigue. The 
patient experienced a significant weight loss of 24 kg in 
the last six months. Laboratory tests are presented in Ta-
ble 1. 
 Peripheral blood count shows Eosinophils 0%, Baso-
phils 0%, Stab 2%, Segment 26%, Lymphocytes 20%, 
Monocytes 7%, Myelocytes 4%, Metamyelocytes 2%, 
Blast 6% and Atypical Mononuclear Cell of 33%. Pe-
ripheral blood examination indicates the loose distribu-
tion of erythrocytes, mild anisocytosis (normocytes, mi-
crocytes), and mild poikilocytosis (ovalocyte, pear-
shaped cell). The estimated platelet count is decreased, 
and the giant platelet is positive but predominantly nor-
mal. The leukocyte count is increased, shift to the left, 
vacuolize neutrophils (+), atypical lymphocytes (+), 
with the impression: acute hematological malignancy. 
Bone marrow aspiration (BMA), and cytochemical 
staining were suggested for further examinations. BMA 
(Figure 1,2,3) showed an increase in lymphocyte activity 
by 91% with 64% of lymphoblast, large cell size with a 
wider cytoplasm, 1 to 3 nuclei together with suppression 
of granulopoiesis and erythropoiesis, and a decline in 
megakaryocytes confirmed the diagnosis of ALL-L2. 
Positive immunophenotyping results on HLA-DR, 
CD10, CD19, CD20, which according to the FAB crite-
ria, support the Line-B lymphoid subtype (Figure 4). 
 The patient was given two bags of packed red cell 
leukocyte-depleted transfusions and four bags of con-
centrate platelets before starting the chemotherapy regi-
men. Obstetric ultrasound was performed and indicated 
a single live intrauterine fetus, breech presentation with 
an estimated fetal weight of 758 gram, FHR: 150 times 
per minute, not in labor, negative HIS, and reactive car-
diotocography (CTG). 
 The chemotherapy regimen was following the Indo-
nesian Protocol of Acute Lymphoblastic Leukemia 
2013.8 The chemotherapy began with an induction phase 
consisting of Vincristine 2 mg/IV weekly and 100 mg of 
oral prednisone for six weeks. The phase is suggested to 
eradicate detectable leukemia cells in peripheral blood 
and bone marrow, moreover, returning the normal hem-
atopoiesis. Despite mild nausea and vomiting, the pa-
tient's appetite increases and weight gain; no alopecia 
nor febrile neutropenia were reported during chemother-
apy.  
 Fetal monitoring was performed with CTG and FHR 
before and after chemotherapy. Pregnancy was main-
tained, and planned termination was set at 34 weeks of 
gestation because of chemotherapy hematological tox-
icity in the last 4 weeks of pregnancy. The fetus was fi-
nally delivered at 32 weeks of gestation by section cesar-
ean (SC) due to premature rupture of the membrane. An 
alive baby girl weighed 1700 grams was born, APGAR 
Score 8/9/9. There were no defects, either clinically or 
hematological features, at the time. The patient shall con-
tinue the chemotherapy regimen to the consolidation 
phase. However, it is unfortunate that the patient lost to 
follow-up thus both treatment and surveillance are im-
possible to be done. 
 
DISCUSSION  
 ALL is rare in adults and even more uncommon in 
pregnancy. In the previous study, the incidence of acute 
leukemia reported a single case per 75000 pregnancies, 
with only 28% cases of ALL.9 The management of all 
cancer types in pregnancy is a huge challenge for physi-
cians, mothers, and the fetus. The long-time follow-up is 
also needed on the children whose mothers receiving 
chemotherapy during pregnancy. Those difficulties are 
more profound in developing countries such as Indone-
sia. Lost to follow-up often happens because of various 
reasons, ranging from adverse effects, lack of health in-
surance coverage, beliefs and cultural considerations, to 
a confusing health system. 
 Our patient represents a great challenge in treating 
leukemia during pregnancy. Higher risk of other preg-
nancy complications on her age (36), remarkable weight 
loss during pregnancy, and bycitopenia indicated that 
closed monitoring should be performed to reach the treat-
ment goals. The risk of bleeding and infection increased 
on the delivery and higher risk of premature rupture of 
the membrane. The consequence of leukemia in preg-
nancy can be lead by leukemia itself or lead by chemo-
therapy-induced.10 The timing of fetal exposure to 
chemotherapeutic agents is one of the main factors of 
pregnancy outcome. 
 According to the morphology FAB of bone marrow 
smears in this patient, the cell distribution was suggestive 
of ALL-L2, which consists of larger lymphoblast cells 
but vary in size; chromatin is coarser with one or more 
nucleoli. Immunophenotyping is performed using bone 
marrow blood samples to differentiate between T-cell or 
B-cell leukemia. Adjusting the CD markers owned by our 
health facilities in these patients, it was found HLA-DR 
(+), CD10 (+), CD19 (+), CD20 (+) so that it supports the 
L-Line B lymphoid image. CD19 antigen appears earliest 
during B cell ontogeny and is expressed in almost all 
cases of B-lineage ALL. 
 The currently available guideline in Indonesia for 
ALL refers to the Indonesian Acute Lymphoblastic Leu-
kemia 2013 protocol. However, the consideration of 
pregnancy condition in ALL is still not specified. ALL 
chemotherapy regimes usually have a higher dose com-
pared to solid tumor. The prognosis of patients made 
through age, cytogenetic assessment, white blood cell 
count, and the duration to reach CR. It is advisable to start 
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of gestational age because the outcome of delayed ther-
apy is way worse. 
 ALL is a heterogeneous disease at the genetic level. 
Chromosome analysis is used to prognostic considera-
tion, and a predictive biomarker to provide subtype, out-
come, and drug response information. In ALL, existing 
of Philadelphia chromosome is important to determining 
chemotherapy regimen, as TKI highly improved the CR 
of ALL with the positive mutation. However, in our case, 
the cytogenetic and molecular examination was not per-
formed due to several reasons. The chromosomal exam-
ination would not differ the chemotherapy regimen be-
cause the safety issue of TKI on pregnancy has not been 
established. The pro and cons of TKI on pregnancy have 
been debated for quite some time; TKI was reported to 
causes adverse events and congenital malformation in 
several literatures. Still, many critics also came for its 
validity. In this case, TKI was decided not to deliver to 
the patient, and further follow-up treatment showed an 
improved overall condition.  
 At that time the family refused to do chromosome 
analysis because it wont make big changes in therapeutic 
regimen for saving mother and the baby, considering the 
regimen that had been used is single chemotherapy : vin-
cristine, to lower the side effect of chemotherapy but still 
should be considered later for continuing the regimen of 
chemotherapy in order to achieved a complete remission. 
 
CONCLUSION  
 ALL is not a common occurrence during pregnancy. 
Treatment is challenging for doctors, patients, and the 
unborn fetus. In this case report, induction chemotherapy 
was performed while maintaining the pregnancy as it en-
tered the 2nd trimester. The baby was delivered at 32 
weeks by CS on obstetric indications. Complications in 
pregnancy, including infection and bleeding, should be 
predicted at delivery because of anemia, neutropenia, 
and thrombocytopenia in the patient. This report aimed 
to provide insight into clinical judgment and decision-
making with a risk-benefit assessment in future similar 
cases. In this case the patient was having a first preg-
nancy in advanced maternal age mother with high social 
value baby and can be treated successfully using single 
regimen of chemotherapy during pregnancy even though 
at the first time administered to hospital the mother come 
with critical clinical presentation. The suggestion of fol-
low-up chromosome analysis/cytogenetic examination 
is still needed for the continuation of the therapeutic reg-
imen. The patient and family should better understand 
the prognosis, potential recurrence, child monitoring, 
and the next possible pregnancy outcomes to avoid los-
ing treatment follow-up. 
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